LOK

Katie Larson Ode, MD

Professor, Pediatric Endocrinology & Diabetes

Dr. Larson Ode oversees the Clinical Phenotyping Core with primary expertise in cystic fibrosis related diabetes mellitus and clinical and translational research study design. Her research focuses on the developmental pathophysiology of cystic fibrosis related diabetes mellitus, in which area she is an acknowledged international expert. She is dedicated to supporting high-quality clinical study design and rapid access to human samples for basic scientists and other investigators in support of the Precision Medicine Center for CF community.

Anthony Fischer

Anthony Fischer, MD, PhD

Associate Professor, Pediatric Pulmonary Medicine

Dr. Fisher is a physician-scientist whose research program focuses on mucus production and associated oxidative stress in CF. His laboratory understands mucus obstruction of both the airways and the digestive tract and how bacteria, especially Staphylococcus aureus exploit this problem. His recent publications have demonstrated a potential role for pancreatic enzymes in relieving meconium ileus. They are also investigating whether some Staphylococcus aureus genotypes increase the risk of CF-related diabetes mellitus. 

The Clinical Phenotyping Core provides access to human samples and human subjects, both banked and in real time, to support Precision Medicine Center for CF investigators and collaborators.

Clinical Research Support

  • Human subjects approval- Human subjects compliance, including IRB support (initial submissions, modifications, continuing renewals), staff are fully GCP certified
  • Clinical trial design- assistance with clinical study design, protocol development, development of source documents, data analysis, abstract and manuscript preparation
  • Access to clinical research participants- participant recruitment, consent, conduct of study visits, collaboration with clinical research unit, research billing and ordering for clinical trials
  • Obtaining biological samples- the team can obtain and process samples from human research participants or clinical visits (with appropriate IRB approvals)
  • Clinical research procedures including: Nasal Potential Difference testing, Sweat Chloride testing, Spirometry, Multiple Breath Washout testing, Sputum Induction, Nebulized treatments, continuous glucose monitor placing and download, IATA certified staff.

Access To Human Samples

  • Real time
    • Serum, whole blood, fresh plasma, throat swab, nasal brushing, autopsy specimens, etc.
  • Biobanking and access to stored human data (CF and control)
    • Biobanking (stored biosamples)
      • Blood- plasma, serum, buffy coat, etc
      • Specialized testing such as OGTT samples
      • Sputum
      • Urine
  • Clinical data (stored data)
    • From clinical research protocols (with appropriate IRB approval)
    • With appropriate IRB approvals, from electronic medical records

Highlighted Publications

  • Liu CM, Fischer JL, Zemanick ET, Woods JC, Markarian KK, Fain SB, Froh D, Heltshe SL, Hoffman LR, Humphries SM, Kramer EL, Ode KL, Lewis M, Li DA, Mata J, Milla SS, Niedbalski PJ, Sawatzky BD, Sim MS, Sullivan JS, Trout AT, Goss CH, Taylor-Cousar JL, Beswick DM. The impact of highly effective modulator therapy on sinusitis and dysosmia in young children with cystic fibrosis: a prospective study protocol. ERJ Open Res. 2025 Jan 13;11(1):00137-2024. doi: 10.1183/23120541.00137-2024. PMID: 39811548; PMCID: PMC11726580.
  • Gordon K, Chapman CG, Harklau NM, Ode KL, Wright BA. Improvements in Serum 25(OH)D Following Stoss Dosing in People With Cystic Fibrosis and Variable Adherence to Maintenance Regimens: A Retrospective Chart Review. Health Sci Rep. 2025 Aug 5;8(8):e71142. doi: 10.1002/hsr2.71142. PMID: 40766771; PMCID: PMC12322582.
  • Zirbes CF, Feder A, Pamatmat AJ, Bartels AR, Pitcher NJ, Rozen AL, Teresi M, Krogh J, Regan M, Arnold EA, Hill JJ, Reinhardt LD, Oberto CL, Boyken L, Reeb VC, Moustafa AM, Planet PJ, Fischer AJ. Genetic Concordance of Staphylococcus aureus From Oropharyngeal and Sputum Cultures in People With Cystic Fibrosis. Pediatr Pulmonol. 2025 Jan;60(1):e27475. doi: 10.1002/ppul.27475. PMID: 39785222; PMCID: PMC11715147.
  • Kienenberger ZE, Farber TO, Teresi ME, Milavetz F, Singh SB, Larson Ode K, Thoma T, Weiner RL, Burlage KR, Fischer AJ. Patient and Caregiver Perceptions of Airway Clearance Methods Used for Cystic Fibrosis. Can Respir J. 2023 Jul 28;2023:1422319. doi: 10.1155/2023/1422319. PMID: 37547298; PMCID: PMC10403321.
  • Zirbes CF, Pitcher NJ, Davis JC, Bartels AR, Krogh JD, Teresi M, Farber T, Milavetz F, Pamatmat AJ, Rozen AL, Reinhardt LD, Boyken L, Singh SB, Twait E, Reeb VC, Ford BA, Fischer AJ. Staphylococcus aureus detection from CF respiratory samples is improved using alternative media. J Cyst Fibros. 2022 Sep;21(5):888-889. doi: 10.1016/j.jcf.2022.04.017. Epub 2022 Apr 29. PMID: 35491319; PMCID: PMC10152491.
  • Fischer AJ, Singh SB, LaMarche MM, Maakestad LJ, Kienenberger ZE, Peña TA, Stoltz DA, Limoli DH. Sustained Coinfections with Staphylococcus aureus and Pseudomonas aeruginosa in Cystic Fibrosis. Am J Respir Crit Care Med. 2021 Feb 1;203(3):328-338. doi: 10.1164/rccm.202004-1322OC. PMID: 32750253; PMCID: PMC7874317.
  • Porterfield HS, Maakestad LJ, LaMarche MM, Thurman AL, Kienenberger ZE, Pitcher NJ, Hansen AR, Zirbes CF, Boyken L, Muyskens BL, Pezzulo AA, Singh SB, Twait E, Ford B, Diekema DJ, Reeb V, Fischer AJ. MRSA strains with distinct accessory genes predominate at different ages in cystic fibrosis. Pediatr Pulmonol. 2021 Sep;56(9):2868-2878. doi: 10.1002/ppul.25559. Epub 2021 Jul 16. PMID: 34219414; PMCID: PMC8395597.
  • Granados A, Chan CL, Moheet A, Vigers T, Arbeláez AM, Larson Ode K. The impact of elexacaftor/tezacaftor/ivacaftor on body composition in a small cohort of youth with cystic fibrosis. Pediatr Pulmonol. 2023 Jun;58(6):1805-1811. doi: 10.1002/ppul.26388. Epub 2023 Mar 17. PMID: 36929859.
  • Chan CL, Granados A, Moheet A, Singh S, Vigers T, Arbeláez AM, Yi Y, Hu S, Norris AW, Ode KL. Glycemia and β-cell function before and after elexacaftor/tezacaftor/ivacaftor in youth and adults with cystic fibrosis. J Clin Transl Endocrinol. 2022 Nov 13;30:100311. doi: 10.1016/j.jcte.2022.100311. PMID: 36620757; PMCID: PMC9816065.
  • Fischer AJ, Kilgore SH, Singh SB, Allen PD, Hansen AR, Limoli DH, Schlievert PM. High Prevalence of Staphylococcus aureus Enterotoxin Gene Cluster Superantigens in Cystic Fibrosis Clinical Isolates. Genes (Basel). 2019 Dec 12;10(12):1036. doi: 10.3390/genes10121036. PMID: 31842331; PMCID: PMC6947208.
  • Singh SB, McLearn-Montz AJ, Milavetz F, Gates LK, Fox C, Murry LT, Sabus A, Porterfield HS, Fischer AJ. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor. Pediatr Pulmonol. 2019 Aug;54(8):1200-1208. doi: 10.1002/ppul.24341. Epub 2019 Apr 22. PMID: 31012285; PMCID: PMC6641998.
  • Wright BA, Schuyler DM, Peña T. The rebound effect: Reoccurrence of nasal polyps following discontinuation of a CFTR modulator in a patient with cystic fibrosis sinus disease. Pediatr Pulmonol. 2024 May 15. doi: 10.1002/ppul.27066. Epub ahead of print. PMID: 38751016.
  • Bista SR, Pena T, Schissel ME, Smith LM, Murphy PJ, Dickinson JD. Restless legs syndrome is prevalent in adults with cystic fibrosis and impacts sleep quality. J Cyst Fibros. 2024 Jan;23(1):137-143. doi: 10.1016/j.jcf.2023.10.016. Epub 2023 Nov 15. PMID: 37973438.
  • Beck MR, Hornick DB, Pena TA, Singh SB, Wright BA. Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis. Pediatr Pulmonol. 2023 May;58(5):1569-1573. doi: 10.1002/ppul.26362. Epub 2023 Mar 1. PMID: 36807558.
  • Yi Y, Norris AW, Wang K, Sun X, Uc A, Moran A, Engelhardt JF, Ode KL. Abnormal Glucose Tolerance in Infants and Young Children with Cystic Fibrosis. Am J Respir Crit Care Med. 2016 Oct 15;194(8):974-980. doi: 10.1164/rccm.201512-2518OC. PMID: 27447840; PMCID: PMC5067820.